Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (6858)	7/15/1999 12:50:00 PM
From: biowa	Read Replies (1) \| Respond to of 9719

George, Two points, IMO: 1) No one gives you permission to unblind early, that's a decision you could make (hopefully done in consultation with the FDA and all of your investigators; and you better have a good reason). 2) If by "look-back points" you mean long-term follow-up, that can be done after unblinding. There are also indications and therapies where the FDA might consider (very infrequently) single-blinded studies, etc. for approval. So you may want to be careful in assuming something is fishy (unless it smells bad otherwise...) biowa